Craig A. Wheeler
President & Chief Executive Officer
Mr. Wheeler was previously President of Chiron BioPharmaceuticals, the biotechnology division of Chiron Corporation, where he was responsible for critical facets of the division’s commercial, discovery and development, and business development activities

John E. Bishop
Vice President, Pharmaceutical Sciences & Manufacturing
Dr. Bishop was previously at Millennium Pharmaceuticals where he was most recently responsible for chemical and biologics process development, managing Millennium’s process development group and leading manufacturing efforts for many of Millennium’s small molecule and biologics clinical candidates. Prior to joining Millennium, Dr. Bishop was involved in leading process development efforts on several projects at Dupont Merck Pharmaceuticals. Prior to that, Dr. Bishop worked in medicinal chemistry research.

Steven B. Brugger
Senior Vice President, Strategic Business Operations
Mr. Brugger was previously Vice President at Millennium Pharmaceuticals where he was responsible for building strategic marketing, project and portfolio management capabilities, leading the inflammation and metabolic franchises, and managing multiple pharmaceutical collaborations. Prior to joining Millennium, Mr. Brugger spent 19 years in the pharmaceutical industry, holding positions in product development and marketing at Hoechst, Ayerst, and Novartis. His most recent position before joining Millennium was as Head of Marketing for Novartis' Transplantation, Tissue Engineering, and Immunology Business Unit in the U.S.

Ian D. Fier

Vice President, Development Operations
Mr. Fier was previously Vice President of Clinical Affairs at BioTransplant Incorporated, where he was responsible for building the clinical development organization, formulating product strategy and directing product development activities for both antibody-based therapeutics and medical devices. Prior to joining BioTransplant, he held positions in product development and program management at The Medicines Company and Astra USA, where his responsibilities included the clinical development of several currently marketed products in the cardiovascular, pulmonary, gastrointestinal and internal medicine fields. Mr. Fier began his career as a preclinical pharmacologist at Aventis (Hoechst) before moving into a clinical trial management role.

Barbara Rosengren

Vice President, Strategic Product Development
Mrs. Rosengren was previously Vice President & Development Project Leader at Millennium Pharmaceuticals where she led the project management activities for the Inflammation franchise including co-development activities with Millennium’s partners in this field. Barbara also serves as a guest faculty instructor in the Project Management courses at Massachusetts Biotechnology Council and the Harvard Extension School. Mrs. Rosengren has also held positions at Sandoz and subsequently Novartis Pharmaceuticals in a variety of commercial and project management positions for both the global and US business.

Richard P. Shea
Vice President, Chief Financial Officer
Mr. Shea was previously Chief Operating Officer, CFO and Treasurer at Variagenics, Inc, a pharmacogenomics company, where he assisted in raising over $120 million, including taking Variagenics public. While at Variagenics, Mr. Shea was responsible for Finance, Legal, Investor Relations, Human Resources and Operations. Prior to this, Mr. Shea was VP of Finance at Genetics Institute, Inc. (now Wyeth), and a Senior Manager at PricewaterhouseCoopers.

Lisa Carron Shmerling
Vice President, Legal Affairs
Ms. Shmerling was previously Associate General Counsel at Millennium Pharmaceuticals, Inc., where she led the negotiation of key strategic biotechnology deals and focused on departmental and interdepartmental strategies and operations. Prior to joining Millennium, Ms. Shmerling was a legal consultant to several private and public biopharmaceutical and high-tech companies.

Ganesh Venkataraman, Ph.D.
Founder and Senior Vice President, Research
Dr. Venkataraman is one of Momenta's scientific founders. Prior to founding Momenta, Dr. Venkataraman was a member of the MIT faculty where he pioneered research in the area of analytical techniques for complex carbohydrates. He also served as the Director of Bioinformatics for the Consortium for Functional Glycomics, a multi-million dollar NIH initiative to study the role of complex sugars in biology.

Susan K. Whoriskey, Ph.D.
Vice President, Licensing and Business Development
Dr. Whoriskey joined Momenta at its inception. Previously, she was Senior Director of Licensing at Cubist Pharmaceuticals, Inc., where she was involved in negotiating collaborations with Merck, Pfizer, Novartis and Bristol Myers Squibb as well as the in-licensing of the company's key product from Eli Lilly, daptomycin. In her role as Senior Director, she was also responsible for overseeing the company's intellectual property estate.